Results 41 to 50 of about 9,100 (154)

Barriers to Hepatitis B Treatment: A Multicentre Cross‐Sectional Registry and Survey Study by the Canadian Hepatitis B Network

Liver International, Volume 46, Issue 9, September 2026.
ABSTRACT Background & Aims Chronic hepatitis B (CHB) remains a leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide, yet treatment uptake is suboptimal even in high‐resource settings. This pan‐Canadian study aimed to quantify treatment gaps within the Canadian Hepatitis B Network (CanHepB) Registry, compare characteristics of ...
Hin Hin Ko, Jordyn Vienneau, Curtis L. Cooper, Pam Crotty, Stephen E. Congly, Mayur Brahmania, Alnoor Ramji, Erin Kelly, Angela M. Crawley, Karen Doucette, Vanessa Meier‐Stephenson, Mang Ma, Scott K. Fung, David K. Wong, Jordan Feld, Nabiha Faisal, Kelly Kaita, Carla Osiowy, Magdy Elkhashab, Edward Tam, Alexander Wong, Robert Bailey, Philip Wong, Giada Sebastiani, Tianyan Chen, Brian Conway, David Truong, Keith Tsoi, Carmine Nudo, Julie Zhu, Sébastien Poulin, Abdel‐Aziz Shaheen, Carla S. Coffin   +32 more
wiley   +1 more source

Passive Transfer of Hepatitis B Core Antibody Following Intravenous Ig Administration: Clinical Implications and Considerations

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Background Intravenous Ig (IVIG) is used in the management of a wide array of medical conditions. Passive transfer of hepatitis B core antibody (anti‐HBc) following IVIG administration is a well‐recognized, but often underappreciated phenomenon that can complicate the interpretation of hepatitis B serologies.
Mark McPherson, Alexandra Jianu, Winn Chatham   +2 more
wiley   +1 more source

Short Inter‐Treatment Interval Treatment With Artificial Liver Support System Reduces 90‐Day Transplant‐Free Mortality in Patients With Hepatitis B Virus–Related Acute‐On‐Chronic Liver Failure: A Retrospective Observational Study

Artificial Organs, Volume 50, Issue 8, Page 1145-1152, August 2026.
ALSS short inter‐treatment interval treatment (patients received two ALSS treatments within 48 h) correlates with improved liver function and 90‐day transplant‐free survival of HBV‐ACLF. This result provides a certain theoretical basis for the timing and time interval of ALSS for HBV‐ACLF, enriches the models and contents of ALSS treatment for HBV‐ACLF,
Jingjie Fu, Fang Chen, Wenfeng Yang, Ting Chen, Jian Xu   +4 more
wiley   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, Volume 27, Issue 8, Page 1241-1252, August 2026.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Clinical utility of entecavir for chronic hepatitis B in Chinese patients

Drug Design, Development and Therapy, 2013
Jiyao WangZhongshan Hospital, Fudan University, Shanghai, Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai, People’s Republic of ChinaAbstract: The People’s Republic of China has one of the highest rates of hepatitis B virus (
Wang JY
doaj  

Experience of entecavir therapy in chronic hepatitis B

Журнал инфектологии, 2014
Entecavir is a potent and selective guanosine analogue that has demonstrated a significant antiviral efficacy against hepatitis B virus. The purpose of this article was to characterize the response to entecavir and it portability.
E. V. Esaulenko, J. S. Alikjan, O. Y. Emelyanjva, T. A. Stasishkis, A. Y. Kovelenov   +4 more
doaj   +1 more source

Monitoring of the Cascade of Care in Patients With Chronic HBV in Primary Care Clinics in Australia

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT To achieve hepatitis B virus (HBV) elimination in Australia, a shift from hospital to community‐based care is needed. This study aimed to describe the prevalence of chronic HBV and uptake of the cascade of care in primary care patients. This prospective cohort study was conducted in 76 urban and regional primary care clinics across Victoria ...
Dina Moussa, Jack Wallace, Jacqui Richmond, Joseph S. Doyle, Long Nguyen, Douglas Boyle, Mark A. Stoové, Jason Asselin, Victoria Polkinghorne, Marvad Ahad, Susanne Glasgow, Kate New, Lena Sanci, Matt Penn, John Furler, Alexander Thompson, Margaret Hellard, Jess Howell   +17 more
wiley   +1 more source

An Exploratory Cost‐Utility Analysis of Screening and Treating Immigrants in Canada for Hepatitis D

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT Hepatitis D is common among immigrants in Canada, who account for approximately 23% of the population and tend to originate from high‐endemic countries. Mortality rates are notably high among those with chronic infections, and immigrants are less likely to engage in screening and treatment services.
Jiahao Zhao, Diedron Lewis, John‐Michael Gamble, Zahid A. Butt, William W. L. Wong   +4 more
wiley   +1 more source

Chronic hepatitis B and hematological malignancies

Клиническая онкогематология, 2013
The active usage of monoclonal antibodies in therapy for hematology malignancies made reactivation of hepatitis B virus (HBV) infection one of the major health problems. Monoclonal antibodies are also used in solid tumors, rheumatic, gastroenterological,
A. O. Buyeverov, P. O. Bogomolov
doaj   +1 more source